BACKGROUND:AZD1480 is a novel agent that inhibits Janus-associated kinases 1 and 2 (JAK1 and JAK2). The primary objective of this phase I study was to investigate the safety and tolerability of AZD1480 when administered as monotherapy to patients with solid tumors. METHODS:Thirty-eight patients with advanced malignancies were treated at doses of 10-70 mg once daily (QD) and 20-45 mg b.i.d. RESULTS: Pharmacokinetic (PK) analysis revealed rapid absorption and elimination with minimal accumulation after repeated QD or b.i.d. dosing. Exposure increased in a dose-dependent manner from 10-50 mg. Maximum plasma concentration (Cmax) was attained ∼1 hour after dose, and t1/2 was ∼5 hours. Pharmacodynamic analysis of circulating granulocytes demonstrated maximum phosphorylated STAT3 (pSTAT3) inhibition 1-2 hours after dose, coincident with Cmax, and greater pSTAT3 inhibition at higher doses. The average pSTAT3 inhibition in granulocytes at the highest dose tested, 70 mg QD, was 56% (standard deviation: ±21%) at steady-state drug levels. Dose-limiting toxicities (DLTs) consisted of pleiotropic neurologic adverse events (AEs), including dizziness, anxiety, ataxia, memory loss, hallucinations, and behavior changes. These AEs were generally reversible with dose reduction or treatment cessation. CONCLUSIONS: Whether the DLTs were due to inhibition of JAK-1/2 or to off-target effects is unknown. The unusual DLTs and the lack of clinical activity led to discontinuation of development.
RCT Entities:
BACKGROUND:AZD1480 is a novel agent that inhibits Janus-associated kinases 1 and 2 (JAK1 and JAK2). The primary objective of this phase I study was to investigate the safety and tolerability of AZD1480 when administered as monotherapy to patients with solid tumors. METHODS: Thirty-eight patients with advanced malignancies were treated at doses of 10-70 mg once daily (QD) and 20-45 mg b.i.d. RESULTS: Pharmacokinetic (PK) analysis revealed rapid absorption and elimination with minimal accumulation after repeated QD or b.i.d. dosing. Exposure increased in a dose-dependent manner from 10-50 mg. Maximum plasma concentration (Cmax) was attained ∼1 hour after dose, and t1/2 was ∼5 hours. Pharmacodynamic analysis of circulating granulocytes demonstrated maximum phosphorylated STAT3 (pSTAT3) inhibition 1-2 hours after dose, coincident with Cmax, and greater pSTAT3 inhibition at higher doses. The average pSTAT3 inhibition in granulocytes at the highest dose tested, 70 mg QD, was 56% (standard deviation: ±21%) at steady-state drug levels. Dose-limiting toxicities (DLTs) consisted of pleiotropic neurologic adverse events (AEs), including dizziness, anxiety, ataxia, memory loss, hallucinations, and behavior changes. These AEs were generally reversible with dose reduction or treatment cessation. CONCLUSIONS: Whether the DLTs were due to inhibition of JAK-1/2 or to off-target effects is unknown. The unusual DLTs and the lack of clinical activity led to discontinuation of development.
Authors: J R Grandis; S D Drenning; Q Zeng; S C Watkins; M F Melhem; S Endo; D E Johnson; L Huang; Y He; J D Kim Journal: Proc Natl Acad Sci U S A Date: 2000-04-11 Impact factor: 11.205
Authors: Maria-del-Mar Inda; Rudy Bonavia; Akitake Mukasa; Yoshitaka Narita; Dinah W Y Sah; Scott Vandenberg; Cameron Brennan; Terrance G Johns; Robert Bachoo; Philipp Hadwiger; Pamela Tan; Ronald A Depinho; Webster Cavenee; Frank Furnari Journal: Genes Dev Date: 2010-08-15 Impact factor: 11.361
Authors: Michael Hedvat; Dennis Huszar; Andreas Herrmann; Joseph M Gozgit; Anne Schroeder; Adam Sheehy; Ralf Buettner; David Proia; Claudia M Kowolik; Hong Xin; Brian Armstrong; Geraldine Bebernitz; Shaobu Weng; Lin Wang; Minwei Ye; Kristen McEachern; Huawei Chen; Deborah Morosini; Kirsten Bell; Marat Alimzhanov; Stephanos Ioannidis; Patricia McCoon; Zhu A Cao; Hua Yu; Richard Jove; Michael Zinda Journal: Cancer Cell Date: 2009-12-08 Impact factor: 31.743
Authors: Sergei Grivennikov; Eliad Karin; Janos Terzic; Daniel Mucida; Guann-Yi Yu; Sivakumar Vallabhapurapu; Jürgen Scheller; Stefan Rose-John; Hilde Cheroutre; Lars Eckmann; Michael Karin Journal: Cancer Cell Date: 2009-02-03 Impact factor: 31.743
Authors: Jing Ni; Shaozhen Xie; Shakti H Ramkissoon; Victor Luu; Yu Sun; Pratiti Bandopadhayay; Rameen Beroukhim; Thomas M Roberts; Charles D Stiles; Rosalind A Segal; Keith L Ligon; William C Hahn; Jean J Zhao Journal: Neuro Oncol Date: 2016-07-10 Impact factor: 12.300
Authors: Mahboubeh S Noori; John D O'Brien; Zachary J Champa; Sudhir P Deosarkar; Olivia L Lanier; Chunyan Qi; Monica M Burdick; Frank L Schwartz; Stephen C Bergmeier; Kelly D McCall; Douglas J Goetz Journal: Eur J Pharmacol Date: 2017-03-23 Impact factor: 4.432
Authors: Tiffany R Hodges; Sherise D Ferguson; Hillary G Caruso; Gary Kohanbash; Shouhao Zhou; Timothy F Cloughesy; Mitchel S Berger; George H Poste; Mustafa Khasraw; Sujuan Ba; Tao Jiang; Tom Mikkelson; W K Alfred Yung; John F de Groot; Howard Fine; Lewis C Cantley; Ingo K Mellinghoff; Duane A Mitchell; Hideho Okada; Amy B Heimberger Journal: Oncoimmunology Date: 2016-02-18 Impact factor: 8.110
Authors: Peter J Houghton; Raushan T Kurmasheva; Dmitry Lyalin; John M Maris; E Anders Kolb; Richard Gorlick; C Patrick Reynolds; Min H Kang; Stephen T Keir; Jianrong Wu; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2014-08-17 Impact factor: 3.167
Authors: Jasmine Lau; Shirin Ilkhanizadeh; Susan Wang; Yekaterina A Miroshnikova; Nicolas A Salvatierra; Robyn A Wong; Christin Schmidt; Valerie M Weaver; William A Weiss; Anders I Persson Journal: Cancer Res Date: 2015-08-17 Impact factor: 12.701